• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease.

作者信息

Choi David K, Cohen Nathaniel A, Choden Tenzin, Cohen Russell D, Rubin David T

机构信息

From the University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.

出版信息

Inflamm Bowel Dis. 2023 Oct 3;29(10):1658-1661. doi: 10.1093/ibd/izad012.

DOI:10.1093/ibd/izad012
PMID:36715294
Abstract
摘要

相似文献

1
Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease.炎症性肠病治疗当前预先授权流程所导致的治疗延误。
Inflamm Bowel Dis. 2023 Oct 3;29(10):1658-1661. doi: 10.1093/ibd/izad012.
2
Delays Related to Prior Authorization in Inflammatory Bowel Disease.炎症性肠病相关的预先授权延误。
Pediatrics. 2022 Mar 1;149(3). doi: 10.1542/peds.2021-052501.
3
Insurer-Mandated Medication Utilization Barriers are Associated With Decreased Insurance Satisfaction and Adverse Clinical Outcomes: An Inflammatory Bowel Disease Partners Survey.保险公司规定的药物使用障碍与保险满意度降低和不良临床结局相关：炎症性肠病合作伙伴调查。
Am J Gastroenterol. 2024 Oct 1;119(10):2070-2078. doi: 10.14309/ajg.0000000000002851. Epub 2024 May 2.
4
Advocating for Patients With Inflammatory Bowel Disease: How to Navigate the Prior Authorization Process.倡导炎症性肠病患者：如何应对预先授权流程。
Inflamm Bowel Dis. 2019 Sep 18;25(10):1621-1628. doi: 10.1093/ibd/izz013.
5
The PA System: Is Prior Authorization for Dose Escalation of IBD Biologic Therapy a Tolerable Alternative or a Perpetual Annoyance?预授权系统：炎症性肠病生物治疗剂量递增的预先授权是一种可容忍的选择还是一种持续的困扰？
Dig Dis Sci. 2023 Dec;68(12):4279-4281. doi: 10.1007/s10620-023-08100-2. Epub 2023 Oct 4.
6
Prior Authorization of Biologics in the Management of Inflammatory Bowel Disease.炎症性肠病管理中生物制剂的预先授权
Inflamm Bowel Dis. 2023 Sep 1;29(9):e37. doi: 10.1093/ibd/izad088.
7
Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey.预先授权延误治疗、影响决策并导致炎症性肠病出现不良事件：2022年医疗服务提供者调查
Clin Gastroenterol Hepatol. 2024 Feb;22(2):423-426. doi: 10.1016/j.cgh.2023.06.021. Epub 2023 Jun 30.
8
Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease.生物治疗剂量升级与炎症性肠病患者疾病活动相关的保险批准延迟。
Dig Dis Sci. 2023 Dec;68(12):4331-4338. doi: 10.1007/s10620-023-08098-7. Epub 2023 Sep 19.
9
Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations.预先授权延迟了生物制剂的使用，并与哮喘恶化的风险相关。
Allergy Asthma Proc. 2021 Jan 1;42(1):65-71. doi: 10.2500/aap.2021.42.200101.
10
Burden with No Benefit: Prior Authorization in Congenital Cardiology.负担与无益：先天性心脏病的预先授权。
Pediatr Cardiol. 2024 Jan;45(1):100-106. doi: 10.1007/s00246-023-03255-1. Epub 2023 Sep 26.

引用本文的文献

1
Ustekinumab infusion to subcutaneous transition: Coordinating care and identifying potential gaps.优特克单抗从静脉输注转换为皮下注射：协调护理并识别潜在差距。
J Manag Care Spec Pharm. 2025 Aug;31(8):764-771. doi: 10.18553/jmcp.2025.31.8.764.
2
National perspectives of barriers by insurance and pharmacy benefit managers in pediatric inflammatory bowel disease.保险和药品福利管理人员对儿童炎症性肠病治疗障碍的全国性观点。
JPGN Rep. 2025 Feb 10;6(2):80-90. doi: 10.1002/jpr3.70004. eCollection 2025 May.
3
Prolonged time to treatment of biologics in inflammatory bowel disease: disparities from a retrospective study in a tertiary referral centre in the UK.
炎症性肠病中生物制剂治疗延迟：来自英国一家三级转诊中心回顾性研究的差异
BMC Gastroenterol. 2025 May 9;25(1):352. doi: 10.1186/s12876-025-03909-9.
4
Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy Support.晚期炎症性肠病治疗开始时较高的延迟率与保险延迟、静脉输液以及缺乏药房支持有关。
Clin Transl Gastroenterol. 2025 Mar 1;16(3):e00808. doi: 10.14309/ctg.0000000000000808.
5
Healthcare Access for Patients With Inflammatory Bowel Disease in the United States: A Survey by the Crohn's & Colitis Foundation.美国炎症性肠病患者的医疗服务可及性：克罗恩病和结肠炎基金会的一项调查
Inflamm Bowel Dis. 2025 Jul 7;31(7):1819-1832. doi: 10.1093/ibd/izae237.
6
A primer on copay accumulators, copay maximizers, and alternative funding programs.关于共付额累积器、共付额最大化器及替代筹资计划的入门知识。
J Manag Care Spec Pharm. 2024 Aug;30(8):883-896. doi: 10.18553/jmcp.2024.30.8.883.
7
Discordance Between Inflammatory Bowel Disease Specialists and Insurance Authorization Denials-A Survey of Specific Inflammatory Bowel Disease Treatment Scenarios.炎症性肠病专家与保险授权拒绝之间的不一致——特定炎症性肠病治疗方案的调查
Crohns Colitis 360. 2023 Dec 30;6(1):otad082. doi: 10.1093/crocol/otad082. eCollection 2024 Jan.
8
Barriers to optimizing inflammatory bowel disease care in the United States.美国优化炎症性肠病护理的障碍。
Therap Adv Gastroenterol. 2023 May 5;16:17562848231169652. doi: 10.1177/17562848231169652. eCollection 2023.